Proventus
Outcome Result Success
Treat the Disease -
UK Charity No 1131517
Time Waits for Nobody
Working Together to Make a Difference
Working Together to Make a Difference
UK Charity No 1131517
Feb 2010 -
Tysabri has been plagued for years by rare cases of progressive multifocal leukoencephalopathy, or PML, which can cause swelling of the brain that is usually fatal. It is mostly seen in patients with immune deficiencies.
The biotech drug is marketed by Cambridge, Mass.-
The Food and Drug Administration said in a statement it has confirmed a total of
31 cases of PML since mid-
In the new labeling, FDA notes there have been no reports of PML in patients taking Tysabri for less than 12 months. In patients taking the drug for two to three years the rate of PML is one case per 1,000 patients.
The new labeling also warns of a complication of PML, known as Immune Reconstitution Inflammatory Syndrome, that can dramatically damage patients' health even after they have stopped taking Tysabri. The agency urges doctors to monitor patients for signs of inflammation.
Tysabri was approved in November 2004 and pulled from the market the next year due to PML reports. It was reintroduced in July 2006, and has been used by 66,000 people worldwide.
Source -
Tysabri - represents a novel class of MS treatments called selective adhesion molecule
(SAM) inhibitors.
A monoclonal antibody which inhibits the migration of white cells into the central nervous system, thus reducing inflammation. It is licensed for the treatment of very active relapsing – remitting multiple sclerosis in those cases where interferon treatment has failed. The medication is given intravenously once every four weeks.
In MS, white blood cells attack the nervous system because the body mistakes its own nerves for a foreign cell. Tysabri works by reducing the number of white blood cells which can leave the blood and enter the nervous system, therefore reducing the damage to the nervous system.
This mechanism of action is different to that used by treatments that have been used
in treating MS (interferon-
Efficacy:
In clinical trials, Tysabri has been shown to approximately halve the progression of the disabling effects of MS and also decrease the number of MS relapses by approximately two thirds.
Contraindications -
- A patient is allergic (hypersensitive) to any of the ingredients of Tysabri.
- A patient has a serious problem with their immune system (due to a disease, e.g. Leukaemia / HIV, or due to a medicine they are taking or have previously taken.)
- A patient is taking medicines that cannot be used with Tysabri.
- A patient has cancer (unless it is a type of skin cancer called basal cell carcinoma.)
- A patient is / are under 18 years of age.
- A patient is over 65 years of age.
Note.
Clinicians need to consider the occurrence of infusion reactions, with especially
delayed reactions occurring more frequently than previously assumed. Delayed infusion
reactions occurred in 4 of 40 relapse-
Side effects may occur:
- Dizziness .
- Nausea.
- Fatigue.
- Headaches.
- Hypersensitivity (allergic) -
If this is the case, Tysabri treatment will be stopped permanently. - Itchy rash (hives).
- Joint pains.
- Skin reactions.
- Sore throat and runny or blocked nose.
- Shivering or fever.
- Tiredness.
- Urinary tract infection.
- Vomiting.
Adverse side effects may occur:
The very nature of the drugs mechanism of action has led to the detection of a small number of cases of Progressive Multifocal Leukoencephalopathy (PML
is a rare and usually fatal viral disease that is characterized by progressive damage or inflammation of the white matter of the brain at multiple locations. It occurs almost exclusively in people with severe immune deficiency).
This very serious disease of the brain is more likely to occur when taking Tysabri
and so regular MRI scanning needs to be undertaken in all such patients. For this
reason the medication is only to be prescribed in major neuroscience centres, by
specially experienced neurologists. To date, PML has only been reported in patients
taking Tysabri together with other drugs which affect the immune system or in people
whose immune system is not as strong as it should be. Therefore Tysabri is given
as a ‘monotherapy’ i.e. On its own. This means that a person should not take medicines
which affect the immune system at the same time as Tysabri including drugs like interferon-
PML usually leads to severe disability or death.
Tysabri Summary of Product Characteristics November 2007
National Institute for Heath and Clinical Excellence Natalizumab for Adults with Highly Active Relapsing Multiple Sclerosis Technology Appraisel Guidance 127 August 2007.
Scottish Medicines Consortium. Resubmission. Natalizumab 300 mg concentrate for solution infusion (Tysabri®, No (329/06). September 2007.
Source: biogen idec (November 22nd 2007)
Notes
Stopping Tysabri May Worsen MS:
Patients currently taking the drug should not discontinue it without seeking advice, the experts stressed.
"People taking the drugs should talk to a neurologist before," Light continued. "For patients, it just means don't stop taking the drug without talking to your doctor." The findings were published Sept. 12 in the online edition of Neurology.
Tysabri (natalizumab), a monoclonal antibody, has been placed under a cloud of controversy for some time.
The drug works by attaching itself to white blood cells called lymphocytes and preventing them from entering the brain, where they do damage that causes the disabling symptoms of MS. Tysabri had also been used to treat Crohn's disease.
But the drug has had a few awkward moments. It first received U.S. Food and Drug Administration approval in November 2004, only to be pulled from the market three months later after several patients in clinical trials developed a rare but deadly viral infection of the brain called progressive multifocal leukoencephalopathy.
In June 2006, the FDA allowed the drug to return to the market, but with strict conditions.
According to the new guidelines, Tysabri can only be administered by approved doctors,
at infusion sites and pharmacies that register and comply with a patient-
Source - By Amanda Gardner
Health Day Reporter
THURSDAY, Sept. 13 (Health Day News) -
Liver Injury: (Feb 2008)
Biogen Idec and Elan Corp, the company that manufacture Tysabri have reported some people have suffered liver injury as a side effect after taking the drug which is a treatment for Multiple Sclerosis and Crohn's disease.
Regulators updated the product's labelling to highlight liver risks in January 2008,
when it was approved for the new use in the intestinal disorder Crohn's Disease.
The new information instructs doctors to tell patients considering Tysabri about
the potential liver problems. The company issued a warning to doctors that signs
of liver injury appeared in people as early as six days after first taking Tysabri.
People with signs of liver damage, such as jaundice should see a health care professional
as soon as possible.
Biogen spokeswoman Shannon Altimari said “that the cases of
liver injury have been reversible after people stopped taking the medicine and none
of the patients with liver damage needed a transplant or died from the side effect”.
Developing neutralising antibodies:
People using Tysabri may develop neutralising antibodies. This is because Tysabri
is a foreign protein and the body’s immune system naturally produces antibodies against
foreign proteins. Some people continue to produce neutralising antibodies - in this
case called “persistent antibodies”. If this occurs the effectiveness of Tysabri
will be reduced. In trials 6% of patients developed “persistent antibodies” and therefore
stopped treatment with Tysabri.
More detailed information on Tysabri can be found by going to -
Typing Tysabri in the search box and pressing go will give you the option to view a patient information leaflet on Tysabri.
Possible link to Melanoma:
Almost immediately after a 46-
At almost the same time, a 45-
Although these are just two -
"Neurologists who have patients who report a family history of melanoma or have funny
moles should send them to a dermatologist first. Don't just start them on drugs [Tysabri],"
said Dr. John Thomas Mullen, co-
"We don't know if the two are related right now," said Patricia O'Looney, vice president of biomedical research at the National Multiple Sclerosis Society. "There are so many people taking Tysabri, we should go forward with caution... One should always consult with their doctor and go over their personal family history and decide what is best."
Tysabri (natalizumab), a monoclonal antibody that helps treat autoimmune disorders such as MS and Crohn's disease, has had a clouded history. It first received U.S. Food and Drug Administration approval in November 2004, only to be pulled from the market three months later after several patients in clinical trials developed a rare but deadly viral infection of the brain called progressive multifocal leukoencephalopathy.
One of the participants in an earlier study of Tysabri had developed (and subsequently died of) a metastatic melanoma that appeared as soon as he got his first dose of the drug, Mullen said. In a study done before Tysabri received FDA approval, melanomas in mice that were given the drug had an increased tendency to detach from the primary tumor and spread.
Tysabari may have a dampening effect on the immune system that encourages the formation of the potentially deadly skin cancer, the letter stated.
“And now that Tysabri has been approved for people with Crohn's disease, more people may be at risk, although those with no family history of melanoma and no moles probably don't need to worry” Mullen said.
"Doctors should ask for a family history of melanoma and do a quick skin check," he said. "Tysabri isn't the only drug in our arsenal. You could give the patient something else if you were concerned about that."
Source: US News and World Report Copyright © 2008 ScoutNews, LLC. All rights reserved. (07/02/08)
Tysabri-
Biogen Idec Inc. and Elan Corp. reported two confirmed cases of a deadly brain infection in patients taking the multiple sclerosis drug Tysabri, the first since the drug was reintroduced in the U.S. in 2006.
The two patients were in the European Union, Biogen said today in a regulatory filing. The cases of the disease, progressive multifocal Leukoencephalopathy, were confirmed this week, according to the company's statement.
Biogen and Elan voluntarily pulled the drug from the market in February 2005 after three patients unexpectedly contracted the disease, which caused two deaths. Tysabri was reintroduced in July 2006 in the U.S. and sold for the first time in the EU at the same time. One patient had been taking the drug for 17 months and the other took it for 14 months, Biogen said.
"This is going to be fairly disruptive to sales in the United States,'' said Mark J. Schoenebaum, an analyst with Deutsche Bank Securities in New York, by telephone.
"There is a real fear of the unknown here, and I think some patients and physicians are going to take a drug holiday until the company discloses more details.
New Death Reported: (Feb 2009)
An american MS person developed the severe brain infection after receiving tysabri. The MS person had received 14 infusions before being diagnosed with PML. Bloomberg.com
Patient Information Leaflet -
The more you take Tysabri, the more likely a potentially deadly brain infection could occur.
That's what the new label is going to say on the prescription for Tysabri for patients with Multiple Sclerosis.
Biogen Idec Inc. and Elan Corp., the companies manufacturing Tysabri, are adding the new information when prescribing the drug, according to Bloomberg News in a report Saturday (Nov. 7).'
The possiblity of contracting the often-
Tysabri’s PML count climbs to 28
At least one more patient has been diagnosed with a rare, and potentially fatal brain infection after taking natalizumab (Tysabri), the hit drug for multiple sclerosis from Biogen Idec and Elan, according to Biogen CEO James Mullen.
There are now 28 confirmed cases of patients with progressive multifocal leukoencephalopathy
(PML) as of the last count in mid-
Source: XCONOMY Boston © 2007-
Tysabri® -